Evidence map›Paper›PMID 31494365›Full record

ArticleJournal of affective disorders2020

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Naji C Salloum, Maurizio Fava, Rebecca S Hock, Marlene P Freeman, Martina Flynn, Bettina Hoeppner, Cristina Cusin, Dan V Iosifescu, Madhukar H Trivedi, Gerard Sanacora and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of affective disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Potential of Heterogeneous Compounds as Antidepressants: A Narrative Review.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Naji C SalloumMassachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA. Electronic address: nchaayasalloum@mgh.harvard.edu.
Maurizio FavaMassachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA.
Rebecca S HockMassachusetts General Hospital, Harvard Medical School, USA.
Marlene P FreemanMassachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA.
Martina FlynnMassachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA.
Bettina HoeppnerMassachusetts General Hospital, Harvard Medical School, USA.
Cristina CusinMassachusetts General Hospital, Harvard Medical School, USA.
Dan V IosifescuNew York University School of Medicine, Nathan Kline Institute, USA.
Madhukar H TrivediThe University of Texas Southwestern Medical Center, USA.
Gerard SanacoraYale School of Medicine, USA.
Sanjay J MathewBaylor College of Medicine and Michael E. Debakey VA Medical Center, Houston, TX, USA.
Charles DebattistaStanford University School of Medicine, USA.
Dawn F IonescuMassachusetts General Hospital, Harvard Medical School, USA.
George I PapakostasMassachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Neurobiological Underpinnings of Placebo Response in DepressionR01MH102279 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI CUSIN, CRISTINA, FAVA, MAURIZIO · 2015 to 2019
$3.9M
NCATS NIH HHS UL1 TR001863NIDA NIH HHS HHSN271201100006CNIDA NIH HHS HHSN271201100006INIMH NIH HHS HHSN271201100006INIMH NIH HHS R01 MH102279
6 · The paper itself

Abstract

objectiveTo examine the rate and time to relapse for remitters and responders to ketamine in treatment-resistant depression (TRD).

methodsSubjects with TRD were randomized to a single infusion of one of several doses of intravenous ketamine, or midazolam. Using Kaplan-Meier survival function, the current report examines the rate and time to relapse, defined as MADRS ≥ 22, over a period of 30 days, in subjects who achieved remission (MADRS ≤ 10) or response (≥ 50% reduction in MADRS) on day three post-infusion of intravenous ketamine 0.1, 0.5, or 1.0 mg/kg.

resultsOf the 60 randomized participants who received a single ketamine (0.1, 0.5, or 1.0 mg/kg) infusion, 19 (34%) met criteria for remission and 27 (48%) for response, on day 3 post-infusion. A numerical dose-response relationship was observed, with remitters/responders on ketamine 1.0 mg/kg having the lowest relapse rate, followed by ketamine 0.5 mg/kg and 0.1 mg/kg, respectively (% of remitters who relapsed by day 14: 38% with 1.0 mg/kg, 50% with 0.5 mg/kg, 100% with 0.1 mg/kg;% of responders who relapsed by day 14: 30% with 1.0 mg/kg, 50% with 0.5 mg/kg, 80% with 0.1 mg/kg). LIMITATIONS: The sample size was small. No MADRS measurements at day one post-infusion. The study was not powered to assess differences in relapse prevention between different doses of ketamine.

conclusionTime to relapse after successful treatment with a single infusion of ketamine appears to follow a dose-response relationship, where higher dosage leads to increased time to relapse.

Indexed as

AdultDepressive Disorder, Treatment-ResistantFemaleHumansInfusions, IntravenousKetamineMajor Depressive DisorderMaleMiddle AgedRandom AllocationRecurrenceYoung AdultKetamineKetamineMajor depressive disorderRelapseRemissionTreatment-resistant depression

Identifiers

PMID31494365
PMCPMC6803106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.